Pentacel™
Pentacel™ is a biological therapy with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
Clinical Trials (8)
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.
A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)
All 8 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 8